Incyclix Bio, LLC filed a Form D with the Securities and Exchange Commission on 2025-08-22.
Incyclix Bio, LLC filed a Form D notice of an exempt securities offering with the SEC on August 22, 2025. The filing reports $11.25M sold. Its industry group is Pharmaceuticals. It names Patrick Roberts (Executive Officer and member of the Board of Managers.), Fredric Eshelman (Executive Officer and member of the Board of Managers.), Norman Sharpless (Member of the Board of Managers.) (SEC Form D, August 22, 2025).
Is this your company?
Sell to companies like Incyclix Bio, LLC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Incyclix Bio, LLC.
Free to see. No signup.
More on the people and the money behind Incyclix Bio, LLC, from the filings we hold.
Pharmaceuticals raises by companies based in North Carolina, filed within 90 days of this one, largest first.
Get an email when Incyclix Bio, LLC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Incyclix Bio, LLC raises, hires or launches. No email unless you switch it on.
Watch Incyclix Bio, LLC →Get the full cited report on Incyclix Bio, LLC
What the filing shows about Incyclix Bio, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Incyclix Bio, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Incyclix Bio, LLC's address as 600 Park Offices Drive, Suite 355, Durham, NC 27713.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Incyclix Bio, LLC is a registered filer with the SEC (CIK 1916275) and has filed since 2023-07-06. 2 filings are on record, the latest on 2025-08-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Incyclix Bio, LLC's Form D of 2025-08-22 names Patrick Roberts, Fredric Eshelman and Norman Sharpless as its officers, directors or promoters.
Its new offerings report $11.25M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
On the filing as: Executive Officer, Director.
Patrick Roberts is named as Executive Officer and member of the Board of Managers. on the Form D that Incyclix Bio, LLC filed with the SEC on 22 August 2025, one of 3 people that filing names.
On the filing as: Executive Officer, Director.
Fredric Eshelman is named as Executive Officer and member of the Board of Managers. on the Form D that Incyclix Bio, LLC filed with the SEC on 22 August 2025, one of 3 people that filing names.
On the filing as: Director.
Norman Sharpless is named as Member of the Board of Managers. on the Form D that Incyclix Bio, LLC filed with the SEC on 22 August 2025, one of 3 people that filing names.
3 people named on the filing — 2 holding an executive role and 1 as a director only.
Named as of the 2025-08-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Incyclix Bio, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Incyclix Bio, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Incyclix Bio, LLC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Incyclix Bio, LLCYou get an alert in MentionFox the next time this company shows up.
If you're behind Incyclix Bio, LLC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Incyclix Bio, LLC. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/incyclix-bio-llc-form-d-25000001